Iterum Therapeutics plc announced that the first patient has been dosed in its Phase 3 clinical trial, known as REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales (REASSURE), comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin(R) (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTI).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.55 USD | -2.52% | +1.31% | -21.32% |
Apr. 29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
Mar. 28 | Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.32% | 26.32M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections